Vitamin E, one of the most widely studied antioxidant supplements in medicine, has returned to the center of liver research with a new study that puts the vitamin to the test inside a remarkably lifelike laboratory replica of fatty liver disease. Writing in Molecular Biology Reports, a research team based in Iran and Sweden reports that vitamin E treatment reduced fat buildup, dampened oxidative stress, and improved liver cell function in a biomimetic co-culture model of metabolic dysfunction-associated steatotic liver disease, or MASLD, a condition that now affects roughly 30 to 38 percent of adults worldwide and is projected to exceed 55 percent prevalence by the middle of this century.
The work matters because MASLD, which spans a spectrum from simple steatosis to inflammation, fibrosis, cirrhosis, and ultimately hepatocellular carcinoma, has no universally approved pharmacological therapy. Vitamin E has long been considered one of the few nutritional interventions with clinical evidence behind it, but most laboratory studies have relied on simplified single-cell cultures or animal models that poorly reflect human liver biology. The new study attempts to close that gap by building a model that incorporates both hepatocyte-like cells and hepatic stellate cells growing on a hydrogel derived from actual liver tissue.
The team, led by Seyedeh Kiana Teymoorian of the Royan Institute and the University of Science and Culture in Tehran, together with senior authors Massoud Vosough and Abbas Piryaei, constructed their model from two well-characterized human cell lines: Huh-7 hepatocyte-derived cells and LX-2 hepatic stellate cells, mixed at a ratio of four to one. This pairing is not arbitrary. In the living liver, hepatocytes store and metabolize fat, while stellate cells are the quiet fibroblasts that, when provoked by injury and inflammation, transdifferentiate into myofibroblast-like cells that produce collagen and drive fibrosis. Lipid overload in hepatocytes injures them, activates resident macrophages, and ultimately rouses the stellate cells into their fibrotic state, so a model that contains both cell types can capture at least one crucial axis of the disease that monocultures cannot.
What makes the platform distinctive is its substrate. The researchers coated the culture plates with LEMgel, a hydrogel prepared from decellularized sheep liver. To make it, they cut liver tissue into thin slices, stripped away all cellular material using detergents, freeze-dried the remaining scaffold, and dissolved it enzymatically in pepsin and acetic acid until a liquid at 10 milligrams per milliliter remained. Diluted to a coating concentration of 100 micrograms per milliliter, this preparation deposits a fibrous extracellular matrix, most likely rich in collagen, that provides both the structural texture and the biochemical signals of a real hepatic microenvironment. An MTS viability assay confirmed the coating was fully biocompatible, with no significant difference in cell survival between coated and uncoated plates.
With the stage set, the researchers induced disease by feeding the co-culture a fatty cocktail: 330 micromolar oleic acid and 165 micromolar palmitic acid, the two free fatty acids most abundant in the Western diet, delivered in complex with fatty acid-free bovine serum albumin. Two days of exposure produced robust and stable steatosis. Oil Red O staining, which dyes neutral triglycerides red, showed heavy intracellular lipid accumulation that persisted across six days of culture, and Nile Red fluorescence provided independent confirmation. Gene expression analysis sealed the diagnosis: carnitine palmitoyltransferase 1 (CPT-1), the rate-limiting transporter that shuttles long-chain fatty acids into mitochondria; SREBP-1c, the master transcription factor of de novo lipogenesis; and CD36, the fatty acid translocase on the cell surface, were all significantly upregulated compared with untreated controls. The co-culture was, in molecular terms, genuinely steatotic.
Then came the therapy. The team screened five doses of vitamin E, from 20 to 200 micromolar, and found that every dose reduced lipid accumulation, but concentrations of 100 micromolar and above cut it roughly in half compared with the fatty-acid-treated group. Because 100 micromolar achieved maximal benefit at the lowest effective concentration without any cytotoxicity, the researchers selected it for the full four-day treatment protocol. Cell viability, which had sagged under fatty acid exposure, rebounded significantly at every dose tested.
The molecular profile of the treated cells told a coherent story of recovery. Vitamin E downregulated CPT-1, NOX4, the NADPH oxidase enzyme that generates reactive oxygen species, along with SREBP-1c, CD36, and PPAR gamma, all drivers of lipid uptake and synthesis. Meanwhile it upregulated the antioxidant arm of the cellular defense: heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1), two canonical downstream targets of the Nrf2 transcription factor, which functions as the master switch of the oxidative stress response. Superoxide dismutase and glutathione, two pillars of antioxidant chemistry, had both been depleted by fatty acid exposure; vitamin E restored glutathione levels significantly, although SOD secretion did not change measurably, suggesting the vitamin may act primarily through the glutathione system at this dose and duration.
The fibrosis axis of the model responded as well. Fatty acid treatment elevated ACTA-2, the gene encoding smooth muscle alpha actin, and COL1A1, the gene for type I collagen, both classic fingerprints of activated stellate cells. Vitamin E significantly reduced the expression of both. Consistent with this, transforming growth factor beta, the cytokine that activates LX-2 cells and propels fibrogenesis, rose sharply in the diseased model and fell dramatically after treatment. The researchers also tracked markers of hepatocyte maturity: albumin secretion, which had dropped under lipid stress, recovered with vitamin E, while alpha-fetoprotein, an indicator of immature or injured hepatocytes, had risen in the diseased state and fell to half its level after treatment.
At the protein level, Western blotting delivered perhaps the study’s most suggestive mechanistic finding. Both Nrf2 and CES1, a carboxylesterase that hydrolyzes triglycerides and cholesterol esters and sits downstream of Nrf2 signaling, were cut to roughly half their normal levels in the MASLD model. Vitamin E treatment restored both proteins to approximately control levels. Because CES1 governs the breakdown of stored fats, its suppression in fatty liver conditions directly promotes steatosis, and its recovery under vitamin E provides a plausible route by which the vitamin clears intracellular lipids. The authors are careful, however, not to overclaim: because they did not perform Nrf2 inhibition or knockdown experiments, they cannot conclude causally that all of vitamin E’s benefits flow through Nrf2, only that the pathway’s activation accompanied the therapeutic effects.
The physiological plausibility of the findings rests on well-established biochemistry. Vitamin E, a lipid-soluble antioxidant, intercalates into membranes where it neutralizes lipid radicals and interrupts the chain reaction of lipid peroxidation, a process central to the transition from simple steatosis to inflammatory steatohepatitis. Excess hepatic fat drives mitochondrial beta-oxidation into overdrive, flooding the cell with reactive oxygen species, overwhelming antioxidant defenses, stressing the endoplasmic reticulum, and pushing stellate cells toward fibrosis. By quenching radicals at their membrane source and simultaneously boosting Nrf2-driven enzymatic defenses, vitamin E attacks the vicious cycle at two points. The apparent reduction of CPT-1 expression after treatment, rather than an increase, the authors interpret as a sign that the compensatory stress response to lipid overload had subsided, an interpretation that reconciles their result with earlier mouse studies in which vitamin E raised CPT-1 while actively burning fat.
The study has honest limitations. The 2D co-culture omits Kupffer cells and other immune components that fuel inflammation in real livers, it relies on immortalized cell lines rather than primary human hepatocytes, and it lacks direct reactive oxygen species measurements. The authors suggest that future work with Nrf2 inhibitors, siRNA knockdown, primary cells, or organoid systems could firm up the mechanistic picture and extend the findings. Still, they position their platform as a pragmatic middle ground: far cheaper and faster than 3D organoids or animal studies, yet far more faithful to liver physiology than flat monocultures, because it combines cell-cell communication with tissue-derived extracellular matrix.
For a disease projected to become the leading indication for liver transplantation, and for which no drug has yet secured broad regulatory approval, accessible models that can rapidly screen candidate therapies are themselves a form of progress. The Tehran-Stockholm team’s platform, and the vitamin E data it generated, suggest that a humble vitamin, evaluated in a dish that looks and behaves a little more like a liver, can still teach the field something new.Subject of Research: Effects of vitamin E on oxidative stress, steatosis, and Nrf2 signaling in a biomimetic in vitro model of metabolic dysfunction-associated steatotic liver disease (MASLD)
Subject of Research: Biology
Subject of Research: Biology
Article Title: Vitamin E treatment modulates steatotic and attenuates oxidative stress in a MASLD in vitro model
Article References: Teymoorian, S. K., Nouri, K., Choshali, M. A., Hassan, M., Rismani, E., Vosough, M., & Piryaei, A. (2026). Vitamin E treatment modulates steatotic and attenuates oxidative stress in a MASLD in vitro model. Molecular Biology Reports, 53(1), Article 1543. https://doi.org/10.1007/s11033-026-12691-0
Image Credits: AI Generated
DOI: 10.1007/s11033-026-12691-0
Keywords: MASLD, Vitamin E, Nrf2 signaling pathway, oxidative stress, lipid accumulation, LEMgel, hepatic stellate cells, steatosis, liver fibrosis, co-culture model, antioxidant response, CES1
Cite Scienmag News
APA MLA Chicago
Drew Townsend. (September 7, 2026). Vitamin E reduces fat buildup and oxidative stress in liver disease model. Scienmag. https://scienmag.com/vitamin-e-reduces-fat-buildup-and-oxidative-stress-in-liver-disease-model/
Drew Townsend. “Vitamin E reduces fat buildup and oxidative stress in liver disease model.” Scienmag, 7 September 2026, https://scienmag.com/vitamin-e-reduces-fat-buildup-and-oxidative-stress-in-liver-disease-model/. Accessed 7 September 2026.
Drew Townsend. “Vitamin E reduces fat buildup and oxidative stress in liver disease model.” Scienmag. September 7, 2026. https://scienmag.com/vitamin-e-reduces-fat-buildup-and-oxidative-stress-in-liver-disease-model/
Copy citation Download RIS
Tags: advanced liver disease researchadvancements in liver disease research modelsantioxidant therapy for liver diseasebiomimetic liver modelbiomimetic liver models for metabolic dysfunctioneffects of antioxidants on liver fibrosisfatty liver diseasefatty liver disease treatment strategieshepatocellular carcinoma risk mitigationimpact of oxidative stress on liver disease progressionliver cell function improvementliver cell function improvement with antioxidantsliver fibrosis and cirrhosis preventionMASLDmetabolic dysfunction-associated steatotic liver diseasenon-alcoholic fatty liver disease treatmentnutritional interventions for liver healthoxidative stress reductionoxidative stress reduction in fatty liverpreclinical models of MASLDrole of hepatic stellate cells in liver fibrosisVitamin Evitamin E and hepatocellular carcinoma preventionVitamin E supplementation in liver disease
